A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Clinical trial NCT04887519 · COMPLETED

Trial details

NCT number: NCT04887519
Sponsor: Takeda
Status: COMPLETED
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung Anaplastic Lymphoma Kinase

Start date: 2020-12-30
Primary completion: 2023-03-31
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.